Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Brief Report: Association of HIV and HCV With Adverse Coronary Artery Phenotypes in Women: Findings From a Cross-Sectional Study

Shitole SG, Chen E, Naveed M, Xue X, Sharma A, Hanna DB, Anastos K, Kaplan RC, Levsky JM, Tien PC, Radparvar AA, Bortnick AE, Budoff[...]

Urine-guided Hydration and Kidney Injury: Comment

Delaporte A, Maghen B, Grogan T, Legrand M, Joosten A. Urine-guided Hydration and Kidney Injury: Comment. Anesthesiology. 2026 Apr 9. doi: 10.1097/ALN.0000000000006003. Epub ahead of[...]

Mechanisms of resistance to Tmprss6 antisense oligonucleotides in a mouse model of β-thalassemia

Zhang V, Barrett TD, Nemeth E, Ganz T. Mechanisms of resistance to Tmprss6 antisense oligonucleotides in a mouse model of β-thalassemia. Blood. 2026 Apr 9:blood.2026033274.[...]